Caffeine Composition

JP2023548525A5Pending Publication Date: 2024-11-01OYE THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023526861
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-04-23
Filing Date
2021-10-29
Publication Date
2024-11-01

AI Technical Summary

Technical Problem

Existing caffeine compositions have low solubility, making them impractical for use in commercial applications such as promoting emergence from anesthesia and treating opioid addiction or overdose, due to the large volumes required for effective dosages.

Method used

A composition comprising caffeine and sodium benzoate, combined with lactic acid, acetic acid, aspartic acid, or glutamic acid, increases caffeine solubility to over 235 mg/mL, allowing for more practical administration in aqueous solutions.

Benefits of technology

The increased solubility enables efficient delivery of caffeine for anesthesia reversal and opioid overdose treatment, reducing the volume needed and minimizing inactive ingredients, while also providing stability against precipitation and thermal degradation.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

For example, compositions comprising caffeine, sodium benzoate, and one or more of lactic acid, acetic acid, aspartic acid, and glutamic acid, methods for preparing the compositions, and methods for using the compositions, including facilitating emergence from anesthesia and / or reversing the effects of anesthesia, including treating opioid addiction or overdose.
Need to check novelty before this filing date? Find Prior Art

Description

Related applications

[0001] This application claims the benefits and priority of U.S. Provisional Patent Application No. 63 / 107,026, filed on 29 October 2020, and U.S. Provisional Patent Application No. 63 / 178,815, filed on 23 April 2021, and the entire contents of both applications are expressly incorporated herein by reference. [Technical Field]

[0002] This disclosure relates to the field of caffeine compositions. [Background technology]

[0003] Caffeine has potential uses in a variety of commercial applications, including pharmaceutical applications. For example, studies in rats have shown that caffeine, when administered intravenously, promotes recovery from anesthesia. The same has been shown in humans. Anesthetics are known to inhibit the release of neurotransmitters from both neurons and secretory cells. Caffeine has been shown to increase intracellular cAMP levels, which is known to promote neurotransmitter release. In a single-center, double-blind, two-direction crossover study design, participants underwent two general anesthesiasms at least two weeks apart. They were administered a 15 mg / kg caffeine citrate infusion (equivalent to 7.5 mg / kg caffeine), and the results showed a significant reduction in the mean time to recovery from anesthesia (16.5 ± 3.9 (SD) minutes with saline administration, 9.6 ± 5.1 (SD) minutes with caffeine administration (P=0.002)). Non-patent document 1.

[0004] Caffeine and sodium benzoate have been prepared by American Regent, Inc. in single-dose vials for use in recovery from anesthesia, as reported, for example, in Non-Patent Document 2. Standard doses have been reported as 125 mg of caffeine and 125 mg of sodium benzoate per milliliter. In the caffeine and sodium benzoate composition, the median dose administered to patients was 150 mg of caffeine-sodium benzoate, and the maximum dose of caffeine-sodium benzoate was 250 mg. However, the results of this study are inconclusive, possibly due to the limited doses provided.

[0005] According to this disclosure, caffeine may also be effective in treating opioid addiction or overdose. Approximately 500,000 deaths worldwide are attributed to drug use. More than 70% of these deaths are opioid-related, and more than 30% of those deaths are due to overdose. Naloxone, useful in treating overdose, is listed on the World Health Organization's list of essential medicines. Rising opioid use in the United States has contributed to the decades-long epidemic known as the “opioid crisis.” The U.S. is the largest consumer of opioids, accounting for approximately 80% of global use. In 2019, an estimated 10.1 million people aged 12 and older in the U.S. misused opioids. Specifically, 9.7 million misused prescription painkillers and 745,000 used heroin (Non-Patent Literature 3). During the opioid crisis, an average of 128 people died each day from overdoses in the U.S. (Non-Patent Literature 4). Opioid overdose, even if not fatal, has serious adverse effects on health.

[0006] In 2016, the opioid-related hospitalization rate in the United States was 297 per 100,000 people, and in 2017, a total of 967,615 non-fatal drug overdoses were treated in emergency departments in the United States. Between 2012 and 2017, the proportion of naloxone administration events (multiple doses counted as one event) increased by 75.1%, from 573.6 doses per 100,000 emergency medical service events to 1004.4 doses.

[0007] The duration of action of naloxone is 30 to 60 minutes. Naloxone is a non-selective and competitive opioid receptor antagonist. Because the duration of action of most opioids is longer than that of naloxone, and because opioids may remain in the body if the patient's physiological ability to metabolize and / or clear opioids before, during, and / or after an overdose is reduced, multiple doses of naloxone may be necessary in the treatment of opioid overdose.

[0008] Naloxone therapy presents several challenges due to its limited duration of action for opioid overdose treatment. For example, multiple doses are often required, which can be inconvenient, especially in mobile transport or emergency room settings. Furthermore, naloxone tends to cause respiratory problems, which must be monitored and / or managed.

[0009] However, the low solubility of caffeine is well known. For example, in order to act effectively as an awakening agent from anesthesia, sufficient caffeine must be delivered via an appropriate drug delivery route. The solubility of caffeine at room temperature is 16 mg / mL, and when combined with the 754 mg of caffeine needed to awaken a 100 kg person in instructions related to awakening from anesthesia (used in clinical trials), this corresponds to a dose greater than 47 mL. This amount is too much and impractical for intravenous bolus administration by clinicians before, during, and / or after surgery. In a typical operating room, many drugs are supplied in 6 mL vials containing up to 5.25 mL of liquid for intravenous delivery. Therefore, a 47 mL dose would require at least 9 vials, which is impractical for hospital use.

[0010] The solubility of caffeine citrate is approximately 56 mg / mL. A dose of 15 mg of caffeine citrate per kilogram of body weight would deliver 1500 mg of caffeine citrate, or approximately 754 mg of caffeine, to a 100 kg person. Therefore, delivering such a dose would require approximately 27 mL of solution (1500 mg / 56 mg / mL), which is still an impractically large dose. [Prior art documents] [Non-patent literature]

[0011] [Non-Patent Document 1] Fong, R. et al., “Caffeine Accelerates Emergence from Isoflurane Anesthesia in Humans,” Anesthesiology, 129(5), pp. 912-920 (2018) [Non-Patent Document 2] Warner et al., “Effects of Caffeine Administration on Sedation and Respiratory Parameters in Patients Recovering from Anesthesia,” Bosnian Journal of Basic Medical Sciences, 18(1), pp. 101-104 (2018) [Non-Patent Document 3] 2019 National Survey on Drug Use and Health (NSDUH) [Non-Patent Document 4] CDC Opioid Basics 2020 [Overview of the project] [Problems that the invention aims to solve]

[0012] Therefore, there is a need for compositions with improved caffeine solubility to enable more practical uses of caffeine in commercial applications. [Means for solving the problem]

[0013] This disclosure provides a composition comprising caffeine and sodium benzoate, with increased caffeine solubility, to enable the use of caffeine to promote or reverse the effects of anesthesia. This composition also enables the use of caffeine to treat opioid intoxication or overdose, either when administered alone or in combination with naloxone.

[0014] In some aspects of the present disclosure, compositions are provided comprising caffeine, sodium benzoate, and one or more of lactic acid, acetic acid, aspartic acid, and glutamic acid. In another aspect, a composition is provided comprising an aqueous solution of caffeine and sodium benzoate, and means for increasing the solubility of caffeine in the aqueous solution. Further compositions are also provided in aqueous solution form, comprising caffeine with a solubility greater than about 235 mg / mL in the solution.

[0015] Another aspect of the present disclosure provides a composition comprising caffeine, sodium benzoate, and one or more of lactic acid, acetic acid, aspartic acid, and glutamic acid, which is prepared by mixing caffeine, sodium benzoate, and one or more of lactic acid, acetic acid, aspartic acid, and glutamic acid in an aqueous solution.

[0016] Additional aspects of the present disclosure provide a method for promoting recovery from anesthesia or a method for neutralizing the effects of anesthesia, which includes administering a pharmaceutically effective amount of the composition of the present disclosure to a patient undergoing a medical procedure using an anesthetic.

[0017] In yet another aspect of the present disclosure, there is provided the use of a pharmaceutically effective amount of a composition comprising caffeine, sodium benzoate, and one or more of lactic acid, acetic acid, aspartic acid, and glutamic acid for treating a host mammal undergoing a medical procedure using an anesthetic.

[0018] In yet a further additional aspect of the present disclosure, there is provided the use of a pharmaceutically effective amount of a composition comprising caffeine, sodium benzoate, and one or more of lactic acid, acetic acid, aspartic acid, and glutamic acid for nullifying the effects of anesthesia, including promoting awakening from anesthesia or reversing the effects of anesthesia, in a host mammal.

[0019] In yet another aspect of the present disclosure, there is provided a kit comprising caffeine, sodium benzoate, and one or more of lactic acid, acetic acid, aspartic acid, and glutamic acid, and optionally also water.

[0020] In an additional aspect of the present disclosure, a stable composition is provided.

[0021] In a further aspect of the present disclosure, there is provided a method of treating a patient suffering from opioid toxicity or overdose, comprising treating a patient in need thereof with a pharmaceutically effective amount of a composition of the present disclosure.

[0022] In yet another aspect of the present disclosure, there is provided the use of a pharmaceutical composition comprising caffeine, sodium benzoate, and one or more of lactic acid, acetic acid, aspartic acid, and glutamic acid for treating a host mammal undergoing treatment for opioid toxicity or overdose.

[0023] Many embodiments are included in the following detailed description.

DETAILED DESCRIPTION OF THE INVENTION

[0024] Various additional embodiments of this disclosure will be described in more detail below. Both the general description above and the detailed description below are illustrative and descriptive and do not limit the scope of this disclosure or the claims. The discussion of specific embodiments or features, including those shown in the examples, serves to illustrate specific exemplary aspects of this disclosure. This disclosure and the claims are not limited to the embodiments specifically discussed herein.

[0025] This disclosure includes compositions comprising caffeine, sodium benzoate, and one or more of lactic acid, acetic acid, aspartic acid, and glutamic acid. The compositions may also contain water and may be in the form of a solution such as an aqueous solution.

[0026] The composition also includes an aqueous solution of caffeine and sodium benzoate, and means for increasing the solubility of caffeine in the aqueous solution. The composition itself may be an aqueous composition. An exemplary means for increasing the solubility of caffeine in an aqueous solution of caffeine and sodium benzoate is lactic acid. Additional exemplary means for increasing the solubility of caffeine in an aqueous solution of caffeine and sodium benzoate are acetic acid, aspartic acid, and glutamic acid.

[0027] The composition also includes caffeine in aqueous solution form with a solubility greater than approximately 235 mg / mL in the solution. Such a composition may further contain sodium benzoate. The composition may also contain one or more of, for example, lactic acid, acetic acid, aspartic acid, and glutamic acid.

[0028] The compositions of this disclosure also include those comprising caffeine, sodium benzoate, and one or more C2-C5 carboxylic acids such as lactic acid, aspartic acid, acetic acid, or glutamic acid. Another composition comprises caffeine, sodium benzoate, and one or more C4-C5 amino acids such as aspartic acid or glutamic acid. Yet another composition comprises caffeine, sodium benzoate, and one or more C2-C5 carboxylic acid alcohols such as lactic acid. Yet another composition comprises one or more C2-C5 dicarboxylic acids such as aspartic acid or glutamic acid. Any such composition may further contain water and may be in the form of a solution.

[0029] The compositions of this disclosure may have improved caffeine solubility and be stable compositions. In many embodiments, caffeine is added to a solution of sodium benzoate and dissolved, then additional water is added, followed by the final addition of one or more of, for example, lactic acid, acetic acid, aspartic acid, and glutamic acid. Due to the improved solubility, the compositions of this disclosure are suitable for commercial applications such as caffeine delivery to promote awakening from anesthesia or to counteract the effects of anesthesia, including reversing the effects of anesthesia. The compositions may also be used alone or in combination with naloxone to treat opioid intoxication or overdose.

[0030] When measuring the solubility of caffeine in the compositions of this disclosure, a solid was typically added and dissolved, and water was gradually added until all the solid was in solution. In some examples (e.g., RP1-49-2; RP1-49-3; RP1-49-4; RP1-49-5; and RP1-57-5), the concentration of caffeine in the solution represented the amount of caffeine in the solution with a specified amount of added material, rather than measuring solubility. Such solutions were unsaturated with respect to caffeine. In other examples (e.g., RP1-60-1; RP1-60-2; and RP1-62-4), a slurry was prepared, and water was added until the solid dissolved. Thus, these concentrations more accurately reflect the solubility of caffeine.

[0031] For example, by mixing lactic acid with caffeine and sodium benzoate in various combinations, it was possible to achieve a higher caffeine solubility than previously reported, such as in RP1-62-4, which was measured to have a solubility of 396 mg / mL. Therefore, in these and other embodiments, the solubility of caffeine in compositions of the present disclosure, such as those containing caffeine, sodium benzoate, one or more of lactic acid, acetic acid, aspartic acid, and glutamic acid, and water, can be greater than approximately 235 mg / mL, or 236 mg / mL or more, or 237 mg / mL or more, or 238 mg / mL or more, or 240 mg / mL or more, or 250 mg / mL or more, or 250 mg / mL or more. Examples include approximately 240 mg / mL to 500 mg / mL, approximately 300 mg / mL to 450 mg / mL, approximately 300 mg / mL to 400 mg / mL, approximately 340 mg / mL to 420 mg / mL, approximately 360 mg / mL to 400 mg / mL, approximately 250 mg / mL to 400 mg / mL, approximately 350 mg / mL to 400 mg / mL, approximately 260 mg / mL to 500 mg / mL, and approximately 260 mg / mL to 400 mg / mL.

[0032] The stability of the caffeine compositions is also described herein. At least some of the compositions of this disclosure are stable against precipitate formation. For example, at least some of the compositions do not show precipitate after a period of at least one week at ambient temperature (e.g., 20°C to 22°C) or operating room temperature (e.g., 12°C to 18°C). In some embodiments, no precipitate formed for longer than eight weeks at these temperatures, and even under refrigerated conditions (e.g., 3°C to 5°C or -2°C). In some embodiments, no precipitate formed for longer than three months, regardless of whether the composition was under refrigerated conditions or not.

[0033] In additional embodiments, at least some compositions of the present disclosure are thermally stable when exposed to a temperature of 135°C for 45 minutes. Thermal stability can be evaluated, for example, by HPLC chemical stability assessment. The absence of additional extra peaks in the composition after exposure to these conditions indicates that the components in the composition have not decomposed into other chemical species. Thermal stability under these conditions indicates that the composition should ultimately be sterilizable.

[0034] In this disclosure, solubility and concentration measurements are used with the word “approximately” to describe the measurements. For example, with respect to solubility, this term represents the variation introduced by the measurement technique, which in this case is approximately 0–2%. Where a value or range mentioned for solubility, concentration, or other indicated parameter is modified by the term “approximately,” the exact value or range also forms an embodiment of this disclosure.

[0035] Tables 1A, 1B, and 1C show specific data parameters for eight examples of compositions of caffeine, sodium benzoate, and water. Lactic acid was also included in seven of the materials. Methods for preparing the compositions are described in Examples 2 and 3. For each composition, the mass or volume of the materials used, the molecular weight of each component, the concentration of lactic acid used, and the lactic acid density are indicated. The relative composition of the composition by mass and equivalents is also calculated there, and the pH is reported.

[0036] Formula RP1-57-5 is a composition containing equal masses of caffeine and sodium benzoate, with no added lactic acid. As shown, the found solubility was 235 mg of caffeine per 1 mL. For RP1-49-2;-3;-4; and -5, the caffeine concentration was found to be 250 mg / mL, although no attempt was made to determine the limiting amount of caffeine in these compositions. Therefore, these compositions are unsaturated. For comparison, saturation conditions were attempted and approached for RP1-60-1;-2; and RP1-62-4. The maximum concentration achieved was approximately 396 mg / mL of caffeine. At such concentrations, only 1.9 mL of solution is needed to administer 7.5 mg / kg (754 mg / 396 mg / mL of caffeine) to a 100 kg human. This makes such concentrations feasible for commercial applications in medicine and food, as it minimizes not only the total amount required but also the mass of the inactive component delivered.

[0037] [Table 1A]

[0038] [Table 1B]

[0039] [Table 1C]

[0040] The compositions of this disclosure may include, for example, caffeine to sodium benzoate molar ratios of about 1:1.0 to about 1:1.5, for example, about 1:1.0 to about 1:1.45 or about 1:1.3 to about 1:1.5 or about 1:1.3 to about 1:1.45, for example, 1:1.1, 1:1.15, 1:1.2, 1:1.25, 1:1.3, 1:1.35, 1:1.4, 1:1.45 and 1:1.5. In these and other embodiments, the molar ratio of caffeine to the total number of moles of lactic acid, acetic acid, aspartic acid, and glutamic acid may be about 1:0.1 to about 1:0.3, for example, 1:0.11, 1:0.12, 1:0.13, 1:0.14, 1:0.15, 1:0.16, 1:0.17, 1:0.18, 1:0.19, 1:0.2, 1:0.21, 1:0.22, 1:0.23, 1:0.24, 1:0.25, 1:0.26, 1:0.27, 1:0.28, 1:0.29, 1:0.3. The composition may also include a molar ratio of sodium benzoate to the total number of moles of lactic acid, acetic acid, aspartic acid, and glutamic acid of about 1:0.15 to about 1:0.18.

[0041] The pH of the compositions of this disclosure is often about 5 to about 6, for example, about 5.80 to about 5.92 or about 5.70 to about 5.90, and includes about 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8 and about 5.9. Other examples of pH include about 5.80, 5.81, 5.82, 5.83, 5.84, 5.85, 5.86, 5.87, 5.88, 5.89, 5.90, 5.91 and about 5.92.

[0042] At least some compositions of this disclosure may contain about 15% to about 25% by mass of caffeine, about 15% to about 25% by mass of sodium benzoate, about 1% to about 3% by mass of lactic acid, and about 50% to about 70% by mass of water. Such a range may further include about 15% to about 22% by mass of caffeine, about 16% to about 24% by mass of sodium benzoate, about 1.4% to about 1.8% by mass of lactic acid, and about 50% to about 66% by mass of water.

[0043] In many embodiments, the mass percentage of sodium benzoate is greater than the mass percentage of caffeine. In many embodiments, the difference between the mass percentage of sodium benzoate and the mass percentage of caffeine is about 1% to about 2%. For example, in a composition containing 2690.5 mg of sodium benzoate, 2500.2 mg of caffeine, and 302.505 mg of lactic acid, with water added to a total volume of 6.3 mL, the mass percentage of sodium benzoate is 23.3%, the mass percentage of caffeine is 21.7%, and the difference in mass percentages is about 1.6%.

[0044] In some embodiments, the compositions of the present disclosure contain less than 14% by mass of lactic acid (or alternatively, the total mass of lactic acid, acetic acid, aspartic acid, and glutamic acid), for example, about 1% to about 3% by mass of lactic acid. These and other compositions may contain more than 30% by mass of water, for example, more than 50% by mass of water. The compositions may also contain a mass percentage of caffeine higher than the mass percentage of lactic acid (or alternatively, the total mass percentage of lactic acid, acetic acid, aspartic acid, and glutamic acid).

[0045] Further embodiments of the composition of the present disclosure include caffeine, sodium benzoate, lactic acid, and water; The composition is released in the form of an aqueous solution; The molar ratio of caffeine to sodium benzoate is approximately 1:1.3 to 1:1.45; The molar ratio of sodium benzoate to lactic acid is approximately 1:0.15 to 1:0.18; The solubility of caffeine in aqueous solution is 250 mg / mL or higher.

[0046] When formulated, the compositions of this disclosure may be in a solid-dry state and then optionally redissolved in water. The solid-dry compositions can be administered to a patient by themselves according to the methods of this disclosure. For example, they can be made into thin films and administered to a patient in that form.

[0047] In some embodiments, the compositions of the present disclosure are pharmaceutical compositions which may optionally contain one or more pharmaceutically acceptable excipients. Exemplary excipients include preservatives, antioxidants, and buffers, and any combination of two or more of these. Examples of preservatives include parabens and parabens. Examples of antioxidants include ascorbic acid, bisulfites, and thioglycerols. Examples of buffers include bicarbonates, phosphates, and tromethamine.

[0048] The amount of caffeine administered will be related to the body weight of the individual being treated. This may include doses ranging from approximately 2.5 mg of caffeine per kg of body weight to approximately 15 mg of caffeine per kg of body weight, for example, 7.5 mg / kg, 10 mg / kg, or 12.5 mg / kg. Therefore, the dose may range, for example, from approximately 250 mg of caffeine to approximately 1200 mg of caffeine. One such dose is approximately 750 mg of caffeine.

[0049] This disclosure includes methods for delivering compositions of the disclosure (typically in the form of aqueous solutions) to a patient for the purpose of promoting recovery from anesthesia or for the purpose of neutralizing the effects of anesthesia, such as by reversing the effects of anesthesia. Previous developments of caffeine for such effects have been hindered by its low solubility. The compositions of the disclosure include those in which caffeine has improved solubility. The caffeine composition (such as a pharmaceutical composition) may be administered before, simultaneously with, or after the delivery of anesthesia.

[0050] Typical anesthetics are those that can be administered for surgery or other medical procedures. Anesthetics can be administered by inhalation or delivered intravenously. Inhaled anesthetic gases include halothane, isoflurane, enflurane, desflurane, and sevoflurane. Other anesthetics besides inhaled ones can also be used. NMDA receptor agonists such as ketamine or alpha-2 agonists such as dexmedetomidine can be used. Other examples include etomidate, lidocaine, magnesium, forskolin, theophylline, methylphenidate, preradinant, or various combinations thereof such as preradinant and forskolin. Another example is propofol. Opioids such as fentanyl, remifentanil, morphine, and hydromorphone can also be used.

[0051] When delivered intravenously, for example, the dose can be administered as a bolus, as an infusion, via an infusion line, or via a smaller intravenous bag such as a 50 mL bag. When the dose is supplied as an IV infusion, it can be administered over any appropriate period, such as over 10 minutes. Administration can be done simultaneously with the administration of the anesthetic, before administration, or after administration, for example, 10 minutes before the end of surgery. For example, the composition can be administered during surgery, postoperatively in the recovery room, at any appropriate time after induction or intubation of the patient at the start of surgery, or at any point throughout the surgical procedure to mitigate common anesthetic adverse events such as cardiac depression and hemodynamic instability.

[0052] Awakening from anesthesia typically occurs earlier than in the absence of the caffeine composition of this disclosure. In many embodiments, administration of the composition of this disclosure will not cause the patient to awaken from anesthesia any earlier unless the administration of the anesthetic to the patient is stopped. Awakening may occur, for example, up to 30 minutes earlier, 15 minutes earlier, up to 15 minutes earlier, 1 to 30 minutes earlier, or 15 to 30 minutes earlier. In these and other embodiments, one or more pharmaceutically acceptable excipients may be added to the composition. For example, excipients that can be used in parenteral compositions, such as intravenous compositions, may be added.

[0053] In many embodiments, no alcohols are present in the compositions of this disclosure. Such alcohols include polyols such as glycols. Polyethylene glycol is an example of such a glycol.

[0054] The methods described herein can be applied to accelerate recovery from anesthesia or to neutralize the effects of anesthesia, such as reversing the effects of anesthesia in humans or non-human vertebrates. Examples of non-human animals include companion animals such as dogs and cats, and agricultural animals such as horses, cattle, and pigs.

[0055] Given the increased solubility of caffeine in the compositions of the Disclosure, the compositions can be delivered using various routes of caffeine delivery in the methods of the Disclosure. These include parenteral, intravenous, intramuscular, subcutaneous, and oral routes, such as the buccal or oral mucosal route. In some embodiments, the compositions of the Disclosure, including the pharmaceutical compositions of the Disclosure, are not in oral dosage form. In some embodiments, the compositions of the Disclosure are not contained in capsules. For example, in some embodiments, the compositions of the Disclosure are not in the form of an aqueous solution inside a capsule.

[0056] Accordingly, further embodiments include parenteral pharmaceutical compositions comprising the compositions of the present disclosure. The parenteral compositions may have any suitable dose volume, such as about 2 to about 8 mL. The compositions may be configured for intravenous administration or for intramuscular or subcutaneous routes.

[0057] Multiple embodiments also include the use of the pharmaceutical compositions of this disclosure for treating a host mammal undergoing medical treatment with an anesthetic. The pharmaceutical compositions may comprise one or more pharmaceutically acceptable excipients. Such compositions do not have to be in oral dosage form, optionally. The pharmaceutical compositions may be, for example, in an intravenous administration form, and the host mammal may be human. Alternatively, the host mammal may be a non-human mammal.

[0058] This disclosure also includes the use of the pharmaceutical compositions of this disclosure to promote recovery from anesthesia or to neutralize the effects of anesthesia in a host mammal such as a human. Methods for neutralizing the effects of anesthesia may include, for example, reversing the effects of anesthesia. The pharmaceutical compositions may comprise one or more pharmaceutically acceptable excipients. The compositions may optionally not be in oral dosage form. The pharmaceutical compositions may be, for example, in an intravenous administration form, and the host mammal may be a human. Alternatively, the host mammal may be a non-human mammal.

[0059] The compositions of this disclosure can also be provided to patients receiving naloxone to help overcome the limitations of naloxone due to caffeine's ability to stimulate respiratory responses, and the duration of action can be extended by up to 4-6 hours after administration with caffeine administration. Although not bound by theory, caffeine, as a bronchial smooth muscle relaxant, CNS stimulant, myocardial stimulant, and diuretic, is thought to be able to neutralize the harmful effects of opioid overdose, either on its own or in combination with naloxone.

[0060] Opioid overdose often results in the presence of acute and / or recurrent respiratory depression requiring repeated administration of naloxone. Respiratory depression (i.e., respiratory rate less than 12 breaths / min or apnea without physiological sleep) and oxygen saturation below 90% of room air suggest opioid toxicity, especially when accompanied by stupor and / or miosis. Naloxone administered under current standard treatments results in competitive antagonism of opioid receptors, which leads to respiratory depression, decreased respiratory rate, and / or apnea. Respiratory depression is frequently observed in the treatment of patients with opioid intoxication or overdose of long-acting or sustained-release opioids. Initial management of opioid toxicity includes maintaining adequate oxygen supply through ventilation (respiratory rate greater than 12 breaths / min and oxygen saturation greater than 90%). Failure to support the patient's airway, respiration, and circulation can lead to negative outcomes, morbidity, and death.

[0061] Administration of caffeine, such as caffeine in the compositions of the present disclosure, can be used to manage opioid intoxication or overdose and to alleviate respiratory depression, decreased respiratory rate, and / or apnea. Accordingly, another embodiment of the present disclosure includes a method for treating a patient suffering from opioid intoxication or overdose, comprising administering to the patient a pharmaceutically effective amount of the compositions of the present disclosure (such as a pharmaceutical composition), including by parenteral administration. Such administration may include doses ranging from about 2.5 mg of caffeine per kg of body weight to about 15 mg of caffeine per kg of body weight, including the doses described above for administering the compositions of the present disclosure. Such administration may be performed as an alternative or supplement to the administration of naloxone, which in some embodiments reduces the amount of naloxone required for clinical benefit.

[0062] Opioid addiction is often associated with or directly caused by misadministration of approved medications. When a patient increases the appropriate dose or duration of opioid use beyond acceptable limits, complications and adverse events can occur due to the resulting opioid toxicity. Overdoses are often associated with the use and ingestion of illegal drugs. Overdoses can impair vital systems such as a properly maintained heart rate and respiration, and can lead to life-threatening consequences such as respiratory arrest. Examples of opioids include oxycodone, hydrocodone, morphine, methadone, fentanyl, and heroin.

[0063] The compositions of this disclosure may be administered before, after, or concurrently with naloxone. In some embodiments, administration of the caffeine compositions of this disclosure to patients suffering from opioid intoxication or overdose reduces pulmonary edema, for example, by increasing diuresis. In many embodiments, when administered to patients suffering from opioid intoxication or overdose, the caffeine compositions of this disclosure stimulate the myocardium and increase heart rate, cardiac output and stroke volume and / or mean arterial blood pressure. The route of administration may be, for example, intravenous, intramuscular, or subcutaneous. Administration of the compositions may be by bolus or via infusion or drip line.

[0064] Opioid withdrawal can, in part, be caused by the administration of naloxone. In many embodiments of this disclosure, administration of the caffeine composition of this disclosure to patients suffering from opioid addiction or overdose who have been administered naloxone suppresses the manifestation of the physiological symptoms of opioid withdrawal. Since caffeine targets the opposite physiological effects of opioids, such as reducing norepinephrine stimulation of the brain and mitigating the effects of hypotension through central nervous system stimulation, it can achieve the management of such symptoms.

[0065] Opioid poisoning or overdose may result from polydrug poisoning, such as that involving benzodiazepines. The caffeine compositions of this disclosure may also be used in combination with compounds other than naloxone to treat opioid poisoning or overdose. Such compounds include tapering opioid agonists or alpha-2-adrenergic agonists.

[0066] This disclosure also includes the use of the pharmaceutical compositions of this disclosure for treating a host mammal suffering from opioid addiction or overdose. The pharmaceutical compositions may comprise water and / or one or more pharmaceutically acceptable excipients. Such compositions may optionally not be in oral dosage form. The pharmaceutical compositions may be, for example, in an intravenous administration form, and the host mammal may be human. Alternatively, the host mammal may be a non-human mammal.

[0067] This disclosure also includes methods for preparing caffeine pharmaceutical compositions. Such methods may include: mixing water with sodium benzoate to form a solution; treating the sodium benzoate solution with caffeine; and then adding one or more of lactic acid, acetic acid, aspartic acid, and glutamic acid to form a caffeine pharmaceutical composition. One or more of the added lactic acid, acetic acid, aspartic acid, and glutamic acid may optionally be aqueous solutions. In some embodiments, the pharmaceutical composition is in an intravenous administration form.

[0068] The caffeine pharmaceutical compositions prepared by this method form additional embodiments of the present disclosure. The compositions may comprise one or more pharmaceutically acceptable excipients. The compositions may also be configured for any suitable route of administration, such as intravenous, intramuscular, subcutaneous, buccal, or oral mucosal delivery.

[0069] Other uses of the compositions of this disclosure include caffeine for beverages, foods, and candies, such as confectionery. Because caffeine is bitter, reducing the amount of caffeine in a product allows for an increase in the amount of sweeteners or other non-bitter ingredients, resulting in an improved overall flavor of the product.

[0070] Accordingly, further embodiments of the present disclosure include beverages, foods, or candies containing the compositions of the present disclosure, such as for oral ingestion by mammals. Examples of foods include baked goods made from flour, such as cakes, pastries, donuts, or cookies. These include such foods having one or more toppings or icings containing the compositions of the present disclosure. Foods also include chocolate, and candies include chewing gum and breath fresheners. Exemplary beverages include carbonated drinks, tea, coffee, and energy drinks.

[0071] The compositions of this disclosure may be added to intermediate products during the manufacture of beverages, foods, or candies as flavor enhancers to suppress bitterness or odor, or to make intermediate or final products more palatable. The compositions may also be added after the manufacture of beverages, foods, or candies.

[0072] Exemplary Embodiments Other exemplary embodiments of this disclosure include those shown in the following non-limiting clauses.

[0073] Clause 1 A composition comprising caffeine, sodium benzoate, and one or more of lactic acid, acetic acid, aspartic acid, and glutamic acid.

[0074] Clause 2: The composition according to Clause 1, further comprising water.

[0075] Clause 3 The composition according to Clause 2, wherein the composition is in the form of a solution.

[0076] Article 4 An aqueous solution of caffeine and sodium benzoate, Means for increasing the solubility of caffeine in the aqueous solution, A composition containing the following:

[0077] Clause 5 A composition in the form of an aqueous solution containing caffeine at a solubility greater than approximately 235 mg / mL in the solution.

[0078] Clause 6 The composition according to Clause 5, comprising sodium benzoate.

[0079] Clause 7 A composition according to any one of Clauses 1 to 6, comprising lactic acid.

[0080] Clause 8 A composition according to any one of Clauses 1 to 7, comprising acetic acid.

[0081] Clause 9 A composition according to any one of Clauses 1 to 8, comprising glutamic acid.

[0082] Clause 10 A composition according to any one of Clauses 1 to 9, comprising aspartic acid.

[0083] Clause 11 A composition according to any one of Clauses 1 to 6, comprising two or more of lactic acid, acetic acid, aspartic acid, and glutamic acid.

[0084] Clause 12 A composition according to any one of Clauses 1 to 11, comprising sodium benzoate, wherein the molar ratio of caffeine to sodium benzoate is about 1:1.0 to about 1:1.5.

[0085] Clause 13 The composition according to Clause 12, wherein the molar ratio of caffeine to sodium benzoate is about 1:1.0 to about 1:1.45.

[0086] Clause 14 The composition according to Clause 12, wherein the molar ratio of caffeine to sodium benzoate is about 1:1.3 to about 1:1.50.

[0087] Clause 15 The composition according to Clause 12, wherein the molar ratio of caffeine to sodium benzoate is about 1:1.3 to about 1:1.45.

[0088] Clause 16 The composition according to Clause 12, wherein the molar ratio of caffeine to sodium benzoate is about 1:1.4.

[0089] Clause 17 The composition according to Clause 12, wherein the molar ratio of caffeine to sodium benzoate is about 1:1.45.

[0090] Clause 18 A composition according to any one of Clauses 1 to 17, comprising one or more of lactic acid, acetic acid, aspartic acid, and glutamic acid, wherein the molar ratio of caffeine to the total number of moles of lactic acid, acetic acid, aspartic acid, and glutamic acid is about 1:0.1 to about 1:0.3.

[0091] Clause 19 The composition according to Clause 18, wherein the molar ratio of caffeine to the total number of moles of lactic acid, acetic acid, aspartic acid, and glutamic acid is about 1:0.2.

[0092] Clause 20 The composition according to Clause 18, wherein the molar ratio of caffeine to the total number of moles of lactic acid, acetic acid, aspartic acid, and glutamic acid is about 1:0.21.

[0093] Clause 21 The composition according to Clause 18, wherein the molar ratio of caffeine to the total number of moles of lactic acid, acetic acid, aspartic acid, and glutamic acid is about 1:0.22.

[0094] Clause 22 The composition according to Clause 18, wherein the molar ratio of caffeine to the total number of moles of lactic acid, acetic acid, aspartic acid, and glutamic acid is about 1:0.26.

[0095] Clause 23 A composition according to any one of Clauses 1 to 22, comprising sodium benzoate and one or more of lactic acid, acetic acid, aspartic acid, and glutamic acid, wherein the molar ratio of sodium benzoate to the total number of moles of lactic acid, acetic acid, aspartic acid, and glutamic acid is about 1:0.15 to about 1:0.18.

[0096] Clause 24 The composition according to any one of Clauses 3 to 23, wherein the pH of the composition is about 5 to about 6.

[0097] Clause 25 The composition according to Clause 24, wherein the pH is approximately 5.80 to approximately 5.92.

[0098] Clause 26 The composition according to Clause 24, wherein the pH is approximately 5.70 to approximately 5.90.

[0099] Clause 27 The composition according to any one of Clauses 2 to 4 and Clauses 6 to 26, wherein the solubility of the caffeine is greater than about 235 mg / mL.

[0100] Clause 28 The composition according to any one of Clauses 2 to 27, wherein the solubility of the caffeine is 236 mg / ml or more.

[0101] Clause 29 The composition according to any one of Clauses 2 to 28, wherein the solubility of the caffeine is 238 mg / ml or more.

[0102] Clause 30 The composition according to Clause 29, wherein the solubility of the caffeine is 240 mg / ml or more.

[0103] Clause 31 The composition according to Clause 29, wherein the solubility of the caffeine is 250 mg / mL or more.

[0104] Clause 32 The composition according to Clause 29, wherein the solubility of the caffeine is approximately 240 mg / mL to approximately 500 mg / mL.

[0105] Clause 33 The composition according to Clause 29, wherein the solubility of the caffeine is approximately 300 mg / mL to approximately 400 mg / mL.

[0106] Clause 34 The composition according to Clause 29, wherein the solubility of the caffeine is approximately 300 mg / mL to approximately 450 mg / mL.

[0107] Clause 35 The composition according to Clause 29, wherein the solubility of the caffeine is approximately 340 mg / mL to approximately 420 mg / mL.

[0108] Clause 36 The composition according to Clause 29, wherein the solubility of the caffeine is approximately 360 mg / mL to approximately 400 mg / mL.

[0109] Clause 37 The composition according to Clause 2 or 3, wherein the mass percentage of caffeine is about 15% to about 25%, the mass percentage of sodium benzoate is about 15% to about 25%, the mass percentage of lactic acid is about 1% to about 3%, and the mass percentage of water is about 50% to about 70%.

[0110] Clause 38 The composition according to Clause 37, wherein the mass percentage of caffeine is about 15% to about 22%, the mass percentage of sodium benzoate is about 16% to about 24%, the mass percentage of lactic acid is about 1.4% to about 1.8%, and the mass percentage of water is about 50% to about 66%.

[0111] Clause 39 A composition according to any one of Clauses 1 to 36, comprising less than 14% by mass of lactic acid.

[0112] Clause 40 The composition according to Clause 39, comprising approximately 1% to approximately 3% by mass of lactic acid.

[0113] Clause 41 A composition according to any one of Clauses 1 to 36 and Clauses 39 to 40, comprising more than 30% by mass of water.

[0114] Clause 42 The composition according to Clause 41, comprising 50% by mass or more of water.

[0115] Clause 43 A composition according to any one of Clauses 1 to 36 and Clauses 39 to 42, comprising a mass percentage of caffeine higher than that of lactic acid.

[0116] Clause 44 A composition according to any one of Clauses 1 to 43, comprising sodium benzoate, wherein the difference between the mass percentage of sodium benzoate and the mass percentage of caffeine is 1% to 2% by mass.

[0117] Article 45 A composition comprising caffeine, sodium benzoate, lactic acid, and water, The composition is in the form of an aqueous solution, The molar ratio of caffeine to sodium benzoate is approximately 1:1.3 to 1:1.45, and the molar ratio of sodium benzoate to lactic acid is approximately 1:0.15 to 1:0.18. The solubility of caffeine in the aqueous solution is 250 mg / mL or more. composition.

[0118] Clause 46 The composition according to any one of Clauses 2 to 45, wherein the composition is stable against the formation of precipitates.

[0119] Clause 47 The composition according to Clause 46, which is in the form of an aqueous solution and does not show precipitation after a period of at least one week.

[0120] Clause 48 The composition according to Clause 47, which does not show precipitation after a period of at least eight weeks.

[0121] Clause 49 The composition according to Clause 48, which does not show precipitation after a period of at least three months.

[0122] Clause 50 The composition according to any one of Clauses 2 to 49, wherein the composition is thermally stable when exposed to a temperature of 135°C for 45 minutes.

[0123] Clause 51 The composition according to any one of Clauses 1, 6 to 23, 39 to 40, and 43 to 44, wherein the composition is in a solid-dry state.

[0124] Clause 52 A composition comprising caffeine, sodium benzoate, and lactic acid.

[0125] Clause 53 The composition according to Clause 52, further comprising water.

[0126] Clause 54 The composition according to Clause 53, wherein the composition is in the form of an aqueous solution.

[0127] Clause 55 The composition according to Clause 53 or 54, wherein the composition is stable against the formation of precipitates, or is thermally stable when exposed to a temperature of 135°C for 45 minutes, or both.

[0128] Article 56 A pharmaceutical composition comprising the composition described in any one of Articles 1 to 55 and one or more pharmaceutically acceptable excipients, optionally selected.

[0129] Article 57 The pharmaceutical composition according to Article 56, wherein the amount of caffeine is approximately 250 mg to approximately 1200 mg.

[0130] Article 58 The pharmaceutical composition according to Article 57, wherein the amount of caffeine is approximately 750 mg.

[0131] Clause 59 The pharmaceutical composition according to any one of Clauses 56 to 58, wherein the one or more pharmaceutically acceptable excipients include one or more preservatives, one or more antioxidants, one or more buffers, or any combination of two or more thereof.

[0132] Clause 60 A kit comprising caffeine, sodium benzoate, and one or more of lactic acid, acetic acid, aspartic acid, and glutamic acid.

[0133] Clause 61: The kit described in Clause 60, containing lactic acid.

[0134] Clause 62 The kit as described in Clause 60 or 61, further comprising water.

[0135] Clause 63 A method for promoting awakening from anesthesia or neutralizing the effects of anesthesia, comprising the step of administering to a patient undergoing a medical procedure using an anesthetic agent a pharmaceutically effective amount of any one of Clauses 1 to 59.

[0136] Clause 64 The method described in Clause 63, wherein the administration is parenteral.

[0137] Clause 65 The method according to Clause 63, wherein the administration is intravenous, intramuscular, subcutaneous, buccal, or oral mucosa.

[0138] Clause 66 The method described in any one of Clauses 63 to 65, wherein the administration is by bolus administration.

[0139] Clause 67 The method described in any one of Clauses 63 to 65, wherein the administration is via infusion or intravenous line.

[0140] Clause 68 The method according to any one of Clauses 63 to 67, wherein the administration is performed simultaneously with the administration of the anesthetic to the patient.

[0141] Clause 69 The method described in any one of Clauses 63 to 67, wherein the administration is performed after the delivery of the anesthetic to the patient.

[0142] Clause 70 The method described in any one of Clauses 63 to 67, wherein the administration is performed before the delivery of the anesthetic to the patient.

[0143] Clause 71 The method according to any one of Clauses 63 to 70, wherein the anesthetic is one or more of halothane, isoflurane, enflurane, desflurane, sevoflurane, etomidate, lidocaine, magnesium, forskolin, theophylline, methylphenidate, preradinant, fentanyl, remifentanil, morphine, hydromorphone, and propofol.

[0144] Clause 72 The method according to any one of Clauses 63 to 70, wherein the anesthetic agent is propofol.

[0145] Clause 73 The method according to any one of Clauses 63 to 72, comprising a step of promoting recovery from anesthesia, wherein the recovery from anesthesia is at least 15 minutes earlier than if the composition according to any one of Clauses 1 to 59 were not administered.

[0146] Clause 74 The method according to any one of Clauses 63 to 72, comprising a step of promoting recovery from anesthesia, wherein the recovery from anesthesia is at least 30 minutes earlier than if the composition according to any one of Clauses 1 to 59 were not administered.

[0147] Clause 75 A method according to any one of Clauses 63 to 74, comprising the step of neutralizing the effect of an anesthetic, wherein the method of neutralizing the effect of an anesthetic is the step of reversing the effect of an anesthetic.

[0148] Article 76 Parenteral pharmaceutical composition comprising the composition described in any one of Articles 1 to 59.

[0149] Clause 77 A parenteral pharmaceutical composition according to Clause 76, wherein the dose volume is approximately 2 to approximately 8 mL.

[0150] Clause 78 Parenteral pharmaceutical composition according to Clause 76 or 77, configured for intravenous administration.

[0151] Clause 79 Parenteral pharmaceutical composition according to Clause 76 or 77, configured for use in an intramuscular or subcutaneous pathway.

[0152] Article 80 Use of a pharmaceutical composition comprising caffeine, sodium benzoate, and one or more of lactic acid, acetic acid, aspartic acid, and glutamic acid for the treatment of a host mammal undergoing medical treatment with an anesthetic.

[0153] Clause 81 The use according to Clause 80, wherein the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients.

[0154] Clause 82 The use of the pharmaceutical composition as described in Clause 80 or 81, wherein the pharmaceutical composition is not in oral dosage form.

[0155] Clause 83 The use according to any one of Clauses 80 to 82, wherein the pharmaceutical composition is in an intravenous dosage form and the host mammal is human.

[0156] Article 84 Use of a pharmaceutical composition comprising caffeine, sodium benzoate, and one or more of lactic acid, acetic acid, aspartic acid, and glutamic acid for promoting recovery from anesthesia or for neutralizing the effects of anesthesia in a host mammal.

[0157] Article 85 The use described in Article 84, wherein the mammal is a human.

[0158] Clause 86 The use of the pharmaceutical composition as described in Clause 84 or 85, wherein the pharmaceutical composition is not in oral dosage form.

[0159] Clause 87 The use according to any one of Clauses 84 to 86, wherein the pharmaceutical composition is in an intravenous dosage form and the host mammal is human.

[0160] Clause 88 The use according to any one of Clauses 84 to 87, wherein the method for neutralizing the effect of the anesthetic is a step of reversing the effect of the anesthetic.

[0161] Clause 89 The use described in any one of Clauses 80 to 82, 84, 86 and 88, wherein the host mammal is a non-human mammal.

[0162] Clause 90 A method for preparing a caffeine pharmaceutical composition, comprising the steps of: mixing water with sodium benzoate to form a solution; treating the sodium benzoate solution with caffeine; and then adding one or more of lactic acid, acetic acid, aspartic acid, and glutamic acid to form a caffeine pharmaceutical composition.

[0163] Clause 91 The method according to Clause 90, wherein one or more of lactic acid, acetic acid, aspartic acid, and glutamic acid are aqueous solutions.

[0164] Clause 92 A caffeine pharmaceutical composition prepared by the method described in Clause 90 or 91.

[0165] Clause 93 The caffeine pharmaceutical composition according to Clause 92, further comprising one or more pharmaceutically acceptable excipients.

[0166] Clause 94 The caffeine pharmaceutical composition according to Clause 92 or 93, wherein the pharmaceutical composition is in an intravenous dosage form.

[0167] Clause 95. A caffeine pharmaceutical composition according to Clause 92 or 93, configured for intravenous, intramuscular, subcutaneous, buccal, or oral mucosal delivery.

[0168] Clause 96 A method for treating a patient suffering from opioid addiction or overdose, comprising the step of administering to the patient a pharmaceutically effective amount of any one of Clauses 1 to 59.

[0169] Clause 97 The method described in Clause 96, wherein the administration is parenteral.

[0170] Clause 98 The method according to Clause 96, wherein the administration is intravenous, intramuscular, or subcutaneous.

[0171] Clause 99 The method described in any one of Clauses 96 to 98, wherein the administration is by bolus administration.

[0172] Clause 100 The method according to any one of Clauses 96 to 98, wherein the administration is via infusion or intravenous line.

[0173] Clause 101 The method described in any one of Clauses 96 to 100, wherein naloxone is administered concurrently to the patient.

[0174] Clause 102 The method according to Clause 101, wherein the naloxone is administered concurrently with the step of administering the composition according to any one of Clauses 1 to 59.

[0175] Clause 103 The method according to Clause 101, wherein the naloxone is administered concurrently during the step of administering the composition according to any one of Clauses 1 to 59.

[0176] Clause 104 The method according to Clause 101, wherein the naloxone is administered concurrently after the step of administering the composition according to any one of Clauses 1 to 59.

[0177] Clause 105 The method according to any one of Clauses 96 to 104, wherein the opioid is oxycodone, hydrocodone, morphine, methadone, fentanyl, or heroin.

[0178] Clause 106 Use of a pharmaceutical composition comprising caffeine, sodium benzoate, and one or more of lactic acid, acetic acid, aspartic acid, and glutamic acid for the treatment of a host mammal suffering from opioid addiction or overdose.

[0179] Clause 107 The use according to Clause 106, wherein the pharmaceutical composition further comprises water.

[0180] Clause 108 The use according to Clause 106 or 107, wherein the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients.

[0181] Clause 109 The use described in any one of Clauses 106 to 108, wherein the pharmaceutical composition is not in oral dosage form.

[0182] Clause 110 The use according to any one of Clauses 106 to 109, wherein the pharmaceutical composition is in an intravenous dosage form and the host mammal is human.

[0183] Article 111 A beverage, food, or candy comprising a composition described in any one of Articles 1 to 55.

[0184] Clause 112 A baked food product made from wheat flour, as described in Clause 111, which is a beverage, food or candy.

[0185] Clause 113: A beverage, food or candy as described in Clause 112, which is a cake, pastry, donut or cookie.

[0186] Article 114: A beverage, food or candy as described in Article 111, which is chocolate.

[0187] Clause 115 A beverage, food or candy as described in Clause 111, which is gum or a breath freshener.

[0188] Clause 116 The beverage, food, or candy described in Clause 111, wherein the beverage is a carbonated beverage, tea, coffee, or energy drink.

[0189] Clause 117 A composition comprising caffeine, sodium benzoate, and one or more C2-C5 carboxylic acids.

[0190] Clause 118 A composition comprising caffeine, sodium benzoate, and one or more C4-C5 amino acids.

[0191] Clause 119 A composition comprising caffeine, sodium benzoate, and one or more C2-C5 carboxylic acid alcohols.

[0192] Clause 120 A composition comprising caffeine, sodium benzoate, and one or more C2-C5 dicarboxylic acids.

[0193] Clause 121 A composition according to any one of Clauses 117 to 120, further comprising water.

[0194] Clause 122 The composition according to Clause 121, wherein the composition is in the form of a solution. [Examples]

[0195] Example 1 - Materials, apparatus, and software Examples 2 and 3 of this disclosure used the following materials, apparatus, and software.

[0196] material: • Distilled water (Meijer, lot 39-222, expiration date 10 / 31 / 2020), (also called water) • Lactic acid solution, ≥85%, ACS reagent (EMD Millipore Corp, lot 56169630) (also known as lactic acid) • Caffeine (Acros, lot A0405347), 98.5% Sodium benzoate (TCI, lot FAPHB-JF), >98% Device: • Denver Instrument Company A-250 Balance • Eppendorf Research 1000 pipettes, range of 0.100–5.000 mL • Ultrasonic jewelry breaker (Model O Conx. jewelry cleaner) • Escali Model PRS00S Scale ·Mettler Toledo AG104 balance VWRS Scientific Symphony SB21 pH meter with Cole-Parmer glass electrode and BNC (05991-61) VELP Scientific stirring plate

[0197] Example 2 - Preparation of a composition of caffeine, sodium benzoate, and lactic acid Hundreds of experiments were conducted in designing experimental models to identify caffeine with enhanced solubility in sodium benzoate. Most did not produce caffeine that remained soluble in solution for the desired duration. Several positive results are reported here. The compositions were prepared by the following process using the amounts of materials shown in Tables 2 and 3: A magnetic stirring bar was placed in a 20 mL scintillation vial, and the vial was placed on a stirring plate. All additions were made with stirring. Approximately half of the water was added to the vial, followed by the sodium benzoate, and stirred until dissolved. The appropriate mass of caffeine was added to the vial, and the remaining water was added to the vial. Lactic acid was then added to the vial, and the vial was capped.

[0198] [Table 2]

[0199] [Table 3]

[0200] When samples of each composition were refrigerated at -2°C, they remained clear for more than 8 weeks.

[0201] Example 3 - Additional preparation of a composition of caffeine, sodium benzoate, and lactic acid Sample: RP1-57-5 (235mg:235mg, Caffeine:Sodium Benzoate) 2,350.2 mg of sodium benzoate was accurately weighed and added to a 20 mL scintillation vial containing a stirring bar. 2,350.1 mg of caffeine was accurately weighed and added to the same vial. Next, 10 mL of distilled water was pipetteed into the vial and the vial was capped. The vial was placed on a magnetic stirring plate and stirred at 300 rpm (5 seconds) until all solids were completely dissolved. -1 The mixture was stirred to obtain a solution containing 235 mg of caffeine per 1 mL of solution. The pH was measured to be 8.01.

[0202] Sample: RP1-60-1 A magnetic stirring bar was placed in a 20 mL scintillation vial, and the vial was placed on a stirring plate. Stirring was performed at 300 rpm (5s). -1 While stirring at 300 rpm (5s), 5 mL of distilled water was pipetteed into the vial. 2,597.5 mg of sodium benzoate was accurately weighed and added to the vial. The vial was stirred until the sodium benzoate was completely dissolved. 2,500.3 mg of caffeine was accurately weighed and added to the same vial. 1.25 mL of distilled water was added to the vial, followed immediately by 249 μL of 88.47% by mass lactic acid solution, and the vial was capped. The next day, an additional 1.0 mL of distilled water was added, and the following day, 0.5 mL of distilled water was added. The vial was stirred at 300 rpm (5s) until all solids were completely dissolved. -1 The mixture was stirred to obtain a solution containing 313 mg of caffeine per 1 mL. The pH was measured to be 5.87.

[0203] Sample: RP1-60-2 A magnetic stirring bar was placed in a 20 mL scintillation vial, and the vial was placed on a stirring plate. Stirring was performed at 300 rpm (5s). -1 While stirring at 300 rpm (5s), 5 mL of distilled water was pipetteed into the vial. 2,690.2 mg of sodium benzoate was accurately weighed and added to the vial. The vial was stirred until the sodium benzoate was completely dissolved. 2,500.1 mg of caffeine was accurately weighed and added to the same vial. 1.25 mL of distilled water was added to the vial, followed immediately by 258 μL of 88.47% by mass lactic acid solution, and the vial was capped. The next day, another 1.0 mL of distilled water was added, and the following day, another 0.25 mL of distilled water was added. The vial was stirred at 300 rpm (5s) until all solids were completely dissolved. -1 The mixture was stirred to obtain a solution containing 322 mg of caffeine per 1 mL. The pH was measured to be 5.94.

[0204] Sample: RP1-62-4 (396 mg / mL caffeine, 18% lactic acid relative to sodium benzoate) A magnetic stirring bar was placed in a 20 mL scintillation vial, and the vial was placed on a stirring plate. Stirring was performed at 300 rpm (5s). -1 While stirring at 300 rpm (5s), 5 mL of distilled water was pipetteed into the vial. 2,690.5 mg of sodium benzoate was accurately weighed and added to the vial. The vial was stirred until the sodium benzoate was completely dissolved. 2,500.2 mg of caffeine was accurately weighed and added to the same vial. 1 mL of distilled water was added to the vial, followed immediately by 310 μL of 88.47% by mass lactic acid solution, and the vial was capped. The vial was stirred at 300 rpm (5s) until all solids were completely dissolved. -1 The mixture was stirred to obtain a solution containing 396 mg of caffeine per 1 mL. The pH was measured to be 5.91.

[0205] The solids in all samples remained dissolved for at least three weeks.

[0206] Example 4 - Samples RP1-65-1, RP1-65-2, and RP1-68-1 Sample RP1-62-4 was reproduced in both 10 ml and 100 ml scales (two samples). The order of addition was half water, sodium benzoate, stirred and dissolved, caffeine, the remaining water, and lactic acid. The second addition of water was used to rinse the remaining solid from the glassware. The larger scale sample was formed in a 250 ml Pyrex® glass media bottle containing a large stirring bar. The sample was removed from the stirring plate and stored on a lab bench under ambient conditions.

[0207] Table 4 shows the details of the formulations of the prepared compositions.

[0208] [Table 4]

[0209] The pH values ​​measured approximately two weeks later were 5.78, 5.77, and 5.77 for compositions RP1-65-1, RP1-65-2, and RP1-68-1, respectively. The caffeine solubility for the compositions was 250 mg / ml. All compositions remained clear for longer than three months.

[0210] Example 5 - Composition comprising acetic acid and aspartic acid or glutamic acid Table 5 below summarizes several compositions that achieve a caffeine content of 250 mg / ml with long-term stability.

[0211] [Table 5]

[0212] These formulations were reproduced by substituting lactic acid with acetic acid (glacial acetic acid, VWR Chemicals), aspartic acid (D-aspartic acid (99+%)), or glutamic acid (L-glutamic acid 99%, Aldrich Chemical Co. Inc.). All samples were prepared in 20 ml scintillation vials, with approximately half the amount of water added first, followed by sodium benzoate (stirred until dissolved), then caffeine, the remaining water, and finally the acid. If the acid to be added was solid, the second addition of water was done last, not after the caffeine.

[0213] The acetic acid sample (Table 6) dissolved rapidly within 15 minutes, had essentially the same pH as the lactic acid sample, and remained dissolved for longer than 3 months.

[0214] [Table 6]

[0215] The aspartic acid samples (Table 7) dissolved relatively quickly. After about one month, all solutions turned slightly yellow. After three months, the first two samples formed precipitates, but the last three samples remained clear.

[0216] [Table 7]

[0217] The glutamic acid samples (Table 8) dissolved relatively quickly, within the same day or the following day. After 3 months, the first sample formed a precipitate, but all other samples remained clear.

[0218] [Table 8]

[0219] Example 6 - Batch Manufacturing Method In a batch manufacturing method for producing an exemplary composition comprising caffeine, sodium benzoate, and water, the following materials and apparatus were used.

[0220] material: caffeine Sodium benzoate ·water ·Lactic acid aqueous solution (approx. 88.5%) Device: • Glass media bottle • Spatula • Weighing container • Magnetic stirring element • Glass funnel ·Balances • Pipette, 5000 μL • Stirring plate

[0221] The batch manufacturing method includes the steps described below.

[0222] Place a clean magnetic stirring bar into a clean 250 mL glass media bottle, and stir the bottle on a stirring plate (300 rpm (5s) -1 Place it on top of the )) and accurately measure 30 mL of water (one-third of the total volume of water), record the volume, and add it to the bottle.

[0223] A clean glass funnel was placed over the bottle opening.

[0224] Sodium benzoate (26.9044 g) was accurately weighed into a suitable container, its mass was recorded, and it was slowly added to a funnel using a clean spatula, taking care not to spill any of the powder.

[0225] The funnel, spatula, and weighing container were rinsed with a precisely measured 5 mL aliquot of water and placed in the bottle. A total of 30 mL of water was required for complete rinsing.

[0226] After removing the funnel, the bottle was capped and stirred until the sodium benzoate was completely dissolved. After obtaining a clear solution in the bottle, the cap was removed and a clean glass funnel was placed over the opening of the bottle.

[0227] Caffeine (25.0014 g) was accurately weighed into a suitable container, the mass was recorded, and it was slowly added to the funnel using a clean spatula without spilling the powdered solid. The funnel, spatula, and weighing container were rinsed with accurately measured 5 mL aliquots of water and placed into the bottle. A total of 30 mL of water was required to rinse completely. After removing the funnel, the remaining water (6.9 mL) was accurately measured, the volume was recorded, and added to the bottle.

[0228] Lactic acid (3.1 mL) was accurately measured and immediately added to the bottle, the bottle was capped again, and stirred (300 rpm (5 s -1 )) until all the solids were completely dissolved.

[0229] Stability of the composition after treatment at 135 °C for 45 minutes in Example 7 A 250 mg / mL caffeine, 18% lactic acid:sodium benzoate composition was diluted 10,000-fold, added to a brown HPLC vial, capped tightly, and placed in an oven at 135 °C. After 45 minutes, the vial was removed and analyzed by HPLC.

[0230] The HPLC chromatogram of the non-heated sample showed a proper peak shape with no overlapping peaks. The peak at a retention time of 4.209 minutes corresponded to caffeine, and the peak at a retention time of 7.545 minutes corresponded to sodium benzoate. In the HPLC results for the chemical stability evaluation of the composition, no additional extraneous peaks were observed after exposure to 135 °C for 45 minutes.

[0231] Example 8 - Hypothetical example A 200-pound (approximately 90.7 kg) male who has overdosed on opioids is treated with the caffeine composition of this disclosure, ranging from 2.5 mg caffeine per kg of body weight to 15 mg caffeine per kg of body weight. The caffeine composition of this disclosure is administered IV and co-administered with naloxone. This combination reverses widespread acute and / or recurrent respiratory depression associated with opioid overdose and reduces the dose and frequency of naloxone administration.

Claims

1. A composition comprising caffeine, sodium benzoate, and one or more of lactic acid, acetic acid, aspartic acid, and glutamic acid.

2. The composition of claim 1 further comprising water.

3. The composition of claim 2 , wherein the composition is in the form of a solution.

4. The composition of claim 1 comprising lactic acid.

5. The composition of claim 1, wherein the molar ratio of caffeine to sodium benzoate is from about 1:1.0 to about 1:1.

5.

6. The composition of claim 1, wherein the molar ratio of caffeine to the total number of moles of lactic acid, acetic acid, aspartic acid and glutamic acid is from about 1:0.1 to about 1:0.

3.

7. The composition of claim 1, wherein the molar ratio of sodium benzoate to the total number of moles of lactic acid, acetic acid, aspartic acid and glutamic acid is from about 1:0.15 to about 1:0.

18.

8. 3. The composition of claim 2, wherein the solubility of the caffeine is greater than or equal to 240 mg / ml.

9. Contains caffeine, sodium benzoate, lactic acid, and water; the composition is in the form of an aqueous solution; a molar ratio of caffeine to sodium benzoate of about 1:1.3 to about 1:1.45; a molar ratio of sodium benzoate to lactic acid of about 1:0.15 to about 1:0.18; The solubility of the caffeine in the aqueous solution is 250 mg / mL or more; The composition of claim 1.

10. The composition of claim 2, wherein the composition is thermally stable when exposed to a temperature of 135°C for 45 minutes.

11. A pharmaceutical composition comprising the composition of any one of claims 1 to 10, and optionally one or more pharma- ceutically acceptable excipients.

12. A method for promoting emergence from anesthesia or reversing the effects of anesthesia, comprising administering to a patient undergoing a medical procedure using an anesthetic a pharma- tically effective amount of a composition described in any one of claims 1 to 10.

13. A parenteral pharmaceutical composition comprising a composition according to any one of claims 1 to 10.

14. 14. The parenteral pharmaceutical composition of claim 13, adapted for intravenous administration.

15. 14. The parenteral pharmaceutical composition of claim 13, adapted for intramuscular or subcutaneous route.

16. 13. A method for treating a patient suffering from opioid addiction or overdose, comprising administering to the patient a pharma- tically effective amount of a composition according to any one of claims 1 to 10.